Literature DB >> 9543310

Collaboration with drug treatment by schizophrenic patients with and without psychoeducational training: results of a 1-year follow-up.

W P Hornung1, S Klingberg, R Feldmann, K Schonauer, H Schulze Mönking.   

Abstract

Within a controlled prospective intervention study, schizophrenic outpatients randomly assigned to four treatment groups and one control group were assessed with regard to collaboration with drug treatment. In total, 39.3% of 84 regular attenders of the psychoeducational training programme and 26.6% of 64 control patients reported having persuaded their psychiatrists to modify their medication prescriptions. A total of 8.3% and 7.8%, respectively, modified their medication on their own initiative, although with subsequent approval by the psychiatrist, and 20.2% and 15.6%, respectively, modified their medication after consulting their psychiatrist. With regard to medication management, the groups did not differ either at post-treatment or at follow-up. At follow-up, regular attenders showed a reduced fear of side-effects, increased confidence in their medication and stable confidence in their physician. Among the control subjects, confidence in the medication and in their physician declined, and fear of side-effects increased. Psychoeducational training therefore led to an optimization of patients' attitudes toward treatment, but not to changes in medication management.

Entities:  

Mesh:

Year:  1998        PMID: 9543310     DOI: 10.1111/j.1600-0447.1998.tb09990.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  11 in total

1.  Effects of a Psychoeducation Program for People with Schizophrenia Aimed at Increasing Subjective Well-Being and the Factors Influencing Those Effects: a Preliminary Study.

Authors:  Ayumi Shinozaki; Teruo Hayashi; Hitoshi Okamura
Journal:  Psychiatr Q       Date:  2020-03

Review 2.  Supportive therapy for schizophrenia.

Authors:  Lucy A Buckley; Nicola Maayan; Karla Soares-Weiser; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-04-14

Review 3.  Psychoeducation for schizophrenia.

Authors:  Jun Xia; Lars Bertil Merinder; Madhvi R Belgamwar
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 4.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 5.  Prompts to encourage appointment attendance for people with serious mental illness.

Authors:  S Reda; S Makhoul
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 6.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 7.  Interventions for enhancing medication adherence.

Authors:  Robby Nieuwlaat; Nancy Wilczynski; Tamara Navarro; Nicholas Hobson; Rebecca Jeffery; Arun Keepanasseril; Thomas Agoritsas; Niraj Mistry; Alfonso Iorio; Susan Jack; Bhairavi Sivaramalingam; Emma Iserman; Reem A Mustafa; Dawn Jedraszewski; Chris Cotoi; R Brian Haynes
Journal:  Cochrane Database Syst Rev       Date:  2014-11-20

Review 8.  Cognitive behavioural therapy (group) for schizophrenia.

Authors:  Giuseppe Guaiana; Massimiliano Abbatecola; Ghazaleh Aali; Federica Tarantino; Ikenna D Ebuenyi; Valeria Lucarini; Wei Li; Caidi Zhang; Antonio Pinto
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

9.  Patients' perspectives on what works in psychoeducational groups for schizophrenia: a qualitative study.

Authors:  Ingrid Sibitz; Michaela Amering; Ralf Gössler; Annemarie Unger; Heinz Katschnig
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-08-24       Impact factor: 4.328

10.  Frequency and effects of psychosocial interventions additional to olanzapine treatment in routine care of schizophrenic patients.

Authors:  Michael Linden; Lena Pyrkosch; Hans-Peter Hundemer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.